Navigation Links
Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Date:5/11/2010

PARIS, May 12, 2010 /PRNewswire-FirstCall/ --

- New Outcomes Trial to Expand Evidence for Dronedarone in a Different AF Population

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

In the U.S., Multaq(R) is indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors (i.e., age >70, hypertension, diabetes, prior cerebrovascular accident, left atrial diameter ≥50 mm or left ventricular ejection fraction [LVEF] <40%), who are in sinus rhythm or who will be cardioverted.[i] Multaq(R) is contraindicated in patients with NYHA Class IV heart failure, or NYHA Class II-III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic.

Permanent AF afflicts 50% of patients suffering from AF and these patients are at high risk of major adverse cardiovascular events. The trial rationale was based on post-hoc findings from the landmark ATHENA trial, in which a trend towards reduction of CV hospitalization and death was seen in patients classified as "permanent" (i.e. with AF/AFL at each ECG r
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Sanofi-aventis Announces Second Quarter 2009 Results
11. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... , ... Apex Therapeutics announced today that company CEO, David Broecker provided a ... The presentation took place on Tuesday, June 16 and provided an update on the ... the treatment of pancreatic cancer. A copy of the company overview can be ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... Francisco, CA (PRWEB) , ... June 30, 2015 ... ... FMT Patients , Study will provide new insights on mechanics of fecal microbiota ... a new partnership to study the microbiome of patients undergoing fecal microbiota transplantation ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... ... thanks to a new indoor composting kit from SCD Probiotics. Designed to ... bucket. Bokashi, made using SCD,s probiotic technology, helps accelerate the process and reduces foul ... ...
... 3, 2010, 8:00 AM - 10:00 AM EST (Webcast ... Summary: The World Science Festival launches its first full ... This event will feature a keynote address by Harold Varmus, ... Technology, as well as a live simulcast of the announcement ...
... Sigma-Aldrich Corporation (Nasdaq: SIAL ) will be presenting at the ... 1:15 PM CDT ( 2:15 PM EDT ) in Chicago, IL. ... at http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to access this ... About Sigma-Aldrich: ...
Cached Biology Technology:All Seasons Indoor Composter&#8482; and All Seasons Bokashi&#8482; Provide Easy Way to Recycle Food Waste Right in Your Kitchen 2All Seasons Indoor Composter&#8482; and All Seasons Bokashi&#8482; Provide Easy Way to Recycle Food Waste Right in Your Kitchen 3Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010 2
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, a ... authentication solutions, today announced enhanced functionality of its ... solution.  The enhancements build on the native ... DigitalPersona Altus platform and provide expanded mobile ... In today,s environment of increasing cyber-attacks ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ... Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt Laborkosten ... Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die forensische ... Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte Lösung ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a ... announced that its U.are.U ® 4500 fingerprint ... Eateries, Inc., a San ... chain, to increase security, improve accountability and reduce ... enable instant, non-repudiable identity confirmation for employee sign ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... groundbreaking studies, brain scientists at Carnegie Mellon University and ... differences that characterize the brains of people with autism ... , Previous studies have demonstrated a lower degree ... autism, as well as smaller size of the corpus ...
... of the people responding to an online survey about obesity ... rather than be fat, according to a study by the ... The 4,000 respondents in varying numbers between 15% and 30% ... give up the possibility of having children, be depressed, or ...
... Researchers, working with colleagues at St George's, University of ... entering the body, so rendering them harmless. , Professor ... Northwest Regional Development Agency's Bionow Project of the Year ... prevention of allergies. , "The technology is based on ...
Cached Biology News:Carnegie Mellon researchers discover key deficiencies in brains of people with autism 2Carnegie Mellon researchers discover key deficiencies in brains of people with autism 3Some people would give life or limb not to be fat 2Allergy battle could be won in five years, says scientist 2
... rabbit blood (New Zealand White or Californian ... is refrigerated within 6 hours of collection, ... -20ºC. The serum is then thawed in ... in-house protocol, filtered through a 0.22 micron ...
... Kit provides the reagents to efficiently ... skeletal myotubes. By efficiently promoting myogenic ... tool in studies examining myogenesis, transcription ... for muscle cell replacement therapy. By ...
... The BD Pathway Bioimager is an automated, ... imaging system that has been integrated into ... Pathway was designed to provide high-resolution, automated ... assist in developing better cell-based assays. The ...
... The EZ DNA Methylation Kit uses ... method for DNA methylation analysis. The kit ... that takes place between cytosine and sodium ... The EZ DNA Methylation Kits innovative in-column ...
Biology Products: